{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T20:30:05Z","timestamp":1744921805746},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Paul-Ehrlich-Institut - Bundesinstitut f\u00fcr Impfstoffe und biomedizinische Arzneimittel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Derzeit (Stand Juli 2022) sind in der EU 6 verschiedene COVID-19-Impfstoffe zugelassen. Diese umfassen 2 mRNA-basierte Impfstoffe (BNT162b2, Comirnaty\u00ae und mRNA-1273, Spikevax\u00ae), 2 auf einem adenoviralen Vektor basierende Impfstoffe (AZD1222, Vaxzevria\u00ae und Ad26.COV2.S, Jcovden\u00ae) sowie den Untereinheitenimpfstoff Nuvaxovid\u00ae (NVX-CoV2373) und den Inaktivatvirus-Impfstoff VLA2001. Obgleich diese Impfstoffe auf unterschiedlichen Technologien basieren, ist allen die Verwendung des Spike-Proteins von SARS-CoV\u20112 als Antigen gemein.<\/jats:p><jats:p>Diese \u00dcbersicht beschreibt die Charakteristika ihrer Zusammensetzung, ihre Wirksamkeit und den Einfluss verschiedener Faktoren auf die Wirksamkeit. Des Weiteren wird das Zulassungsverfahren erl\u00e4utert und die Faktoren werden identifiziert, welche zu der bisher noch nicht dagewesenen Schnelligkeit in der Entwicklung und Zulassung von Impfstoffen gegen einen pandemischen Erreger beigetragen haben.<\/jats:p>","DOI":"10.1007\/s00103-022-03600-4","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T19:02:46Z","timestamp":1666119766000},"page":"1237-1243","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["\u00dcbersicht \u00fcber die in der EU zugelassenen COVID-19-Impfstoffe\u00a0\u2013 von der Technologie \u00fcber die klinische Pr\u00fcfung zur Zulassung"],"prefix":"10.1007","volume":"65","author":[{"given":"Eberhard","family":"Hildt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"3600_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","volume":"19","author":"P V\u2019kovski","year":"2021","unstructured":"V\u2019kovski\u00a0P, Kratzel\u00a0A, Steiner\u00a0S, Stalder\u00a0H, Thiel\u00a0V (2021) Coronavirus biology and replication: implications for SARS-CoV\u20112. Nat Rev Microbiol 19:155\u2013170. https:\/\/doi.org\/10.1038\/s41579-020-00468-6","journal-title":"Nat Rev Microbiol"},{"key":"3600_CR2","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41586-020-2665-2","volume":"588","author":"Z Ke","year":"2020","unstructured":"Ke\u00a0Z, Oton\u00a0J, Qu\u00a0K et al (2020) Structures and distributions of SARS-CoV\u20112 spike proteins on intact virions. Nature 588:498\u2013502. https:\/\/doi.org\/10.1038\/s41586-020-2665-2","journal-title":"Nature"},{"key":"3600_CR3","doi-asserted-by":"publisher","first-page":"4257","DOI":"10.1038\/s41598-021-82849-2","volume":"11","author":"RA R\u00f6mer","year":"2021","unstructured":"R\u00f6mer\u00a0RA, R\u00f6mer\u00a0NS, Wallis\u00a0AK (2021) Flexibility and mobility of SARS-CoV-2-related protein structures. Sci Rep 11:4257. https:\/\/doi.org\/10.1038\/s41598-021-82849-2","journal-title":"Sci Rep"},{"key":"3600_CR4","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41594-022-00735-5","volume":"29","author":"SM Costello","year":"2022","unstructured":"Costello\u00a0SM, Shoemaker\u00a0SR, Hobbs\u00a0HT et al (2022) The SARS-CoV\u20112 spike reversibly samples an open-trimer conformation exposing novel epitopes. Nat Struct Mol Biol 29:229\u2013238. https:\/\/doi.org\/10.1038\/s41594-022-00735-5","journal-title":"Nat Struct Mol Biol"},{"key":"3600_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-med-042420-112725","volume":"73","author":"MJ Hogan","year":"2022","unstructured":"Hogan\u00a0MJ, Pardi\u00a0N (2022) mRNA vaccines in the COVID-19 pandemic and beyond. Annu Rev Med 73:17\u201339. https:\/\/doi.org\/10.1146\/annurev-med-042420-112725","journal-title":"Annu Rev Med"},{"key":"3600_CR6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41541-021-00369-6","volume":"6","author":"FX Heinz","year":"2021","unstructured":"Heinz\u00a0FX, Stiasny\u00a0K (2021) Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. NPJ Vaccines 6:104. https:\/\/doi.org\/10.1038\/s41541-021-00369-6","journal-title":"NPJ Vaccines"},{"key":"3600_CR7","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41586-020-2622-0","volume":"586","author":"KS Corbett","year":"2020","unstructured":"Corbett\u00a0KS, Edwards\u00a0DK, Leist\u00a0SR et al (2020) SARS-CoV\u20112 mRNA vaccine design enabled by prototype pathogen preparedness. Nature 586:567\u2013571. https:\/\/doi.org\/10.1038\/s41586-020-2622-0","journal-title":"Nature"},{"key":"3600_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41586-020-2639-4","volume":"586","author":"MJ Mulligan","year":"2020","unstructured":"Mulligan\u00a0MJ, Lyke\u00a0KE, Kitchin\u00a0N et al (2020) Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature 586:589\u2013593. https:\/\/doi.org\/10.1038\/s41586-020-2639-4","journal-title":"Nature"},{"key":"3600_CR9","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1084\/jem.20171450","volume":"215","author":"N Pardi","year":"2018","unstructured":"Pardi\u00a0N, Hogan\u00a0MJ, Naradikian\u00a0MS et al (2018) Nucleoside-modified mRNA vaccines induce potent T follicular helper and germinal center B cell responses. J\u00a0Exp Med 215:1571\u20131588. https:\/\/doi.org\/10.1084\/jem.20171450","journal-title":"J Exp Med"},{"key":"3600_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi\u00a0N, Hogan\u00a0MJ, Porter\u00a0FW, Weissman\u00a0D (2018) mRNA vaccines\u2014a\u00a0new era in vaccinology. Nat Rev Drug Discov 17:261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"key":"3600_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.omtn.2019.02.018","volume":"15","author":"M Baiersd\u00f6rfer","year":"2019","unstructured":"Baiersd\u00f6rfer\u00a0M, Boros\u00a0G, Muramatsu\u00a0H et al (2019) A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA. Mol Ther Nucleic Acids 15:26\u201335. https:\/\/doi.org\/10.1016\/j.omtn.2019.02.018","journal-title":"Mol Ther Nucleic Acids"},{"key":"3600_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtn.2019.01.013","volume":"15","author":"KJ Hassett","year":"2019","unstructured":"Hassett\u00a0KJ, Benenato\u00a0KE, Jacquinet\u00a0E et\u00a0al (2019) Optimization of lipid nanoparticles for Intramuscular administration of mRNA vaccines. Mol Ther Nucleic Acids 15:1\u201311. https:\/\/doi.org\/10.1016\/j.omtn.2019.01.013","journal-title":"Mol Ther Nucleic Acids"},{"key":"3600_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010065","author":"MD Buschmann","year":"2021","unstructured":"Buschmann\u00a0MD, Carrasco\u00a0MJ, Alishetty\u00a0S, Paige\u00a0M, Alameh\u00a0MG, Weissman\u00a0D (2021) Nanomaterial delivery systems for mRNA vaccines. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines9010065","journal-title":"Vaccines (Basel)"},{"key":"3600_CR14","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.nano.2013.12.003","volume":"10","author":"C Lonez","year":"2014","unstructured":"Lonez\u00a0C, Bessodes\u00a0M, Scherman\u00a0D, Vandenbranden\u00a0M, Escriou\u00a0V, Ruysschaert\u00a0J\u2011M (2014) Cationic lipid nanocarriers activate toll-like receptor 2 and NLRP3 inflammasome pathways. Nanomedicine 10:775\u2013782. https:\/\/doi.org\/10.1016\/j.nano.2013.12.003","journal-title":"Nanomedicine"},{"key":"3600_CR15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2105968118","author":"L Zhang","year":"2021","unstructured":"Zhang\u00a0L, Richards\u00a0A, Barrasa\u00a0MI, Hughes\u00a0SH, Young\u00a0RA, Jaenisch\u00a0R (2021) Reverse-transcribed SARS-CoV\u20112 RNA can integrate into the genome of cultured human cells and can be expressed in patient-derived tissues. Proc Natl Acad Sci U S\u00a0A. https:\/\/doi.org\/10.1073\/pnas.2105968118","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3600_CR16","doi-asserted-by":"publisher","first-page":"JC75","DOI":"10.7326\/ACPJ202107200-075","volume":"174","author":"HS Sacks","year":"2021","unstructured":"Sacks\u00a0HS (2021) The single-dose J&J vaccine had 67\u202f% efficacy against moderate to severe-critical COVID-19\u202fat \u226514\u202fd. Ann Intern Med 174:JC75. https:\/\/doi.org\/10.7326\/ACPJ202107200-075","journal-title":"Ann Intern Med"},{"key":"3600_CR17","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41586-020-2608-y","volume":"586","author":"N van Doremalen","year":"2020","unstructured":"van Doremalen\u00a0N, Lambe\u00a0T, Spencer\u00a0A et al (2020) ChAdOx1 nCoV-19 vaccine prevents SARS-CoV\u20112 pneumonia in rhesus macaques. Nature 586:578\u2013582. https:\/\/doi.org\/10.1038\/s41586-020-2608-y","journal-title":"Nature"},{"key":"3600_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","volume":"6","author":"SA Mendon\u00e7a","year":"2021","unstructured":"Mendon\u00e7a\u00a0SA, Lorincz\u00a0R, Boucher\u00a0P, Curiel\u00a0DT (2021) Adenoviral vector vaccine platforms in the SARS-CoV\u20112 pandemic. NPJ Vaccines 6:97. https:\/\/doi.org\/10.1038\/s41541-021-00356-x","journal-title":"NPJ Vaccines"},{"key":"3600_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1146\/annurev-med-012621-102252","volume":"73","author":"C Jacob-Dolan","year":"2022","unstructured":"Jacob-Dolan\u00a0C, Barouch\u00a0DH (2022) COVID-19 vaccines: adenoviral vectors. Annu Rev Med 73:41\u201354. https:\/\/doi.org\/10.1146\/annurev-med-012621-102252","journal-title":"Annu Rev Med"},{"key":"3600_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.74974","author":"E Kowarz","year":"2022","unstructured":"Kowarz\u00a0E, Krutzke\u00a0L, K\u00fclp\u00a0M et al (2022) Vaccine-induced COVID-19 mimicry syndrome. Elife. https:\/\/doi.org\/10.7554\/eLife.74974","journal-title":"Elife"},{"key":"3600_CR21","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.coi.2015.06.006","volume":"35","author":"Y Zhou","year":"2015","unstructured":"Zhou\u00a0Y, Sullivan\u00a0NJ (2015) Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine. Curr Opin Immunol 35:131\u2013136. https:\/\/doi.org\/10.1016\/j.coi.2015.06.006","journal-title":"Curr Opin Immunol"},{"key":"3600_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","volume":"21","author":"AJ Pollard","year":"2021","unstructured":"Pollard\u00a0AJ, Bijker\u00a0EM (2021) A guide to vaccinology: from basic principles to new developments. Nat Rev Immunol 21:83\u2013100. https:\/\/doi.org\/10.1038\/s41577-020-00479-7","journal-title":"Nat Rev Immunol"},{"key":"3600_CR23","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1021\/acscentsci.1c00080","volume":"7","author":"Y Watanabe","year":"2021","unstructured":"Watanabe\u00a0Y, Mendon\u00e7a\u00a0L, Allen\u00a0ER et al (2021) Native-like SARS-coV\u20112 spike glycoprotein expressed by ChAdox1 ncoV-19\/AZD1222 vaccine. ACS Cent Sci 7:594\u2013602. https:\/\/doi.org\/10.1021\/acscentsci.1c00080","journal-title":"ACS Cent Sci"},{"key":"3600_CR24","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1056\/NEJMoa2107659","volume":"385","author":"PT Heath","year":"2021","unstructured":"Heath\u00a0PT, Galiza\u00a0EP, Baxter\u00a0DN et al (2021) Safety and efficacy of NVX-coV2373 Covid-19 vaccine. N\u00a0Engl J Med 385:1172\u20131183. https:\/\/doi.org\/10.1056\/NEJMoa2107659","journal-title":"N Engl J Med"},{"key":"3600_CR25","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1056\/NEJMoa2026920","volume":"383","author":"C Keech","year":"2020","unstructured":"Keech\u00a0C, Albert\u00a0G, Cho\u00a0I et al (2020) Phase 1\u20132 trial of a\u00a0SARS-coV\u20112 recombinant spike protein nanoparticle vaccine. N\u00a0Engl J Med 383:2320\u20132332. https:\/\/doi.org\/10.1056\/NEJMoa2026920","journal-title":"N Engl J Med"},{"key":"3600_CR26","doi-asserted-by":"publisher","first-page":"e41451","DOI":"10.1371\/journal.pone.0041451","volume":"7","author":"JM Reimer","year":"2012","unstructured":"Reimer\u00a0JM, Karlsson\u00a0KH, L\u00f6vgren-Bengtsson\u00a0K, Magnusson\u00a0SE, Fuentes\u00a0A, Stertman\u00a0L (2012) Matrix-M\u2122 adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen. PLoS One 7:e41451. https:\/\/doi.org\/10.1371\/journal.pone.0041451","journal-title":"PLoS One"},{"key":"3600_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1007\/s00103-019-02921-1","volume":"62","author":"R Wagner","year":"2019","unstructured":"Wagner\u00a0R, Hildt\u00a0E (2019) Zusammensetzung und Wirkmechanismen von Adjuvanzien in zugelassenen viralen Impfstoffen. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 62:462\u2013471. https:\/\/doi.org\/10.1007\/s00103-019-02921-1","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"3600_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/v12060622","author":"AS Jureka","year":"2020","unstructured":"Jureka\u00a0AS, Silvas\u00a0JA, Basler\u00a0CF (2020) Propagation, inactivation, and safety testing of SARS-coV\u20112. Viruses. https:\/\/doi.org\/10.3390\/v12060622","journal-title":"Viruses"},{"key":"3600_CR29","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41564-020-00789-5","volume":"5","author":"WS Lee","year":"2020","unstructured":"Lee\u00a0WS, Wheatley\u00a0AK, Kent\u00a0SJ, DeKosky\u00a0BJ (2020) Antibody-dependent enhancement and SARS-CoV\u20112 vaccines and therapies. Nat Microbiol 5:1185\u20131191. https:\/\/doi.org\/10.1038\/s41564-020-00789-5","journal-title":"Nat Microbiol"},{"key":"3600_CR30","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40259-021-00495-6","volume":"35","author":"SB Halstead","year":"2021","unstructured":"Halstead\u00a0SB (2021) Vaccine-associated enhanced viral disease: implications for viral vaccine development. BioDrugs 35:505\u2013515. https:\/\/doi.org\/10.1007\/s40259-021-00495-6","journal-title":"BioDrugs"},{"key":"3600_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.06.009","author":"R Lazarus","year":"2022","unstructured":"Lazarus\u00a0R, Taucher\u00a0C, Brown\u00a0C et al (2022) Safety and immunogenicity of the inactivated whole-virus adjuvanted vaccine VLA2001: a\u00a0randomized, dose escalation, double-blind phase 1\/2 clinical trial in healthy adults. J\u00a0Infect. https:\/\/doi.org\/10.1016\/j.jinf.2022.06.009","journal-title":"J Infect"},{"key":"3600_CR32","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/S0140-6736(22)00152-0","volume":"399","author":"DR Feikin","year":"2022","unstructured":"Feikin\u00a0DR, Higdon\u00a0MM, Abu-Raddad\u00a0LJ et al (2022) Duration of effectiveness of vaccines against SARS-CoV\u20112 infection and COVID-19 disease: results of a\u00a0systematic review and meta-regression. Lancet 399:924\u2013944. https:\/\/doi.org\/10.1016\/S0140-6736(22)00152-0","journal-title":"Lancet"},{"key":"3600_CR33","doi-asserted-by":"publisher","first-page":"22777","DOI":"10.1038\/s41598-021-02321-z","volume":"11","author":"V Rotshild","year":"2021","unstructured":"Rotshild\u00a0V, Hirsh-Raccah\u00a0B, Miskin\u00a0I, Muszkat\u00a0M, Matok\u00a0I (2021) Comparing the clinical efficacy of COVID-19 vaccines: a\u00a0systematic review and network meta-analysis. Sci Rep 11:22777. https:\/\/doi.org\/10.1038\/s41598-021-02321-z","journal-title":"Sci Rep"},{"key":"3600_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10050796","author":"S Hein","year":"2022","unstructured":"Hein\u00a0S, Mhedhbi\u00a0I, Zahn\u00a0T et al (2022) Quantitative and qualitative difference in antibody response against omicron and ancestral SARS-coV\u20112 after third and fourth vaccination. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines10050796","journal-title":"Vaccines (Basel)"},{"key":"3600_CR35","doi-asserted-by":"publisher","first-page":"e85","DOI":"10.1056\/NEJMoa2114228","volume":"385","author":"Y Goldberg","year":"2021","unstructured":"Goldberg\u00a0Y, Mandel\u00a0M, Bar-On\u00a0YM et al (2021) Waning immunity after the BNT162b2 vaccine in Israel. N\u00a0Engl J Med 385:e85. https:\/\/doi.org\/10.1056\/NEJMoa2114228","journal-title":"N Engl J Med"},{"key":"3600_CR36","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/S0140-6736(21)02249-2","volume":"398","author":"N Barda","year":"2021","unstructured":"Barda\u00a0N, Dagan\u00a0N, Cohen\u00a0C et al (2021) Effectiveness of a\u00a0third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study. Lancet 398:2093\u20132100. https:\/\/doi.org\/10.1016\/S0140-6736(21)02249-2","journal-title":"Lancet"},{"key":"3600_CR37","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1056\/NEJMoa2116063","volume":"386","author":"ES Rosenberg","year":"2022","unstructured":"Rosenberg\u00a0ES, Dorabawila\u00a0V, Easton\u00a0D et al (2022) Covid-19 vaccine effectiveness in New York State. N\u00a0Engl J Med 386:116\u2013127. https:\/\/doi.org\/10.1056\/NEJMoa2116063","journal-title":"N Engl J Med"},{"key":"3600_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04778-y","author":"F Muecksch","year":"2022","unstructured":"Muecksch\u00a0F, Wang\u00a0Z, Cho\u00a0A et al (2022) Increased memory B cell potency and breadth after a\u00a0SARS-CoV\u20112 mRNA boost. Nature. https:\/\/doi.org\/10.1038\/s41586-022-04778-y","journal-title":"Nature"},{"key":"3600_CR39","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","volume":"600","author":"F Schmidt","year":"2021","unstructured":"Schmidt\u00a0F, Weisblum\u00a0Y, Rutkowska\u00a0M et al (2021) High genetic barrier to SARS-CoV\u20112 polyclonal neutralizing antibody escape. Nature 600:512\u2013516. https:\/\/doi.org\/10.1038\/s41586-021-04005-0","journal-title":"Nature"},{"key":"3600_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2021-002131","author":"J Hirsh","year":"2022","unstructured":"Hirsh\u00a0J, Htay\u00a0T, Bhalla\u00a0S, Nguyen\u00a0V, Cervantes\u00a0J (2022) Breakthrough SARS-CoV\u20112 infections after COVID-19 immunization. J\u00a0Investig Med. https:\/\/doi.org\/10.1136\/jim-2021-002131","journal-title":"J Investig Med"},{"key":"3600_CR41","doi-asserted-by":"publisher","first-page":"836826","DOI":"10.3389\/fmed.2021.836826","volume":"8","author":"SJR da Silva","year":"2021","unstructured":"da Silva\u00a0SJR, de Lima\u00a0SC, da Silva\u00a0RC, Kohl\u00a0A, Pena\u00a0L (2021) Viral load in COVID-19 patients: implications for prognosis and vaccine efficacy in the context of emerging SARS-coV\u20112 variants. Front Med (Lausanne) 8:836826. https:\/\/doi.org\/10.3389\/fmed.2021.836826","journal-title":"Front Med (Lausanne)"},{"key":"3600_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9070747","author":"R Wagner","year":"2021","unstructured":"Wagner\u00a0R, Hildt\u00a0E, Grabski\u00a0E et al (2021) Accelerated development of COVID-19 vaccines: technology platforms, benefits, and associated risks. Vaccines (Basel). https:\/\/doi.org\/10.3390\/vaccines9070747","journal-title":"Vaccines (Basel)"},{"key":"3600_CR43","doi-asserted-by":"publisher","DOI":"10.1111\/all.14868","author":"R Wagner","year":"2021","unstructured":"Wagner\u00a0R, Mei\u00dfner\u00a0J, Grabski\u00a0E, Sun\u00a0Y, Vieths\u00a0S, Hildt\u00a0E (2021) Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID-19 vaccines in Europe. Allergy. https:\/\/doi.org\/10.1111\/all.14868","journal-title":"Allergy"},{"key":"3600_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.06.058","author":"R Shivji","year":"2022","unstructured":"Shivji\u00a0R, Conocchia\u00a0R, Korakianiti\u00a0E, Jekerle\u00a0V (2022) Considerations for the chemistry, manufacturing and controls (CMC)\u2014quality package for COVID-19 vaccines-interim lessons learnt by the European medicines agency (EMA). Vaccine. https:\/\/doi.org\/10.1016\/j.vaccine.2022.06.058","journal-title":"Vaccine"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-022-03600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-022-03600-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-022-03600-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:06:24Z","timestamp":1670259984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-022-03600-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":44,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1007\/s00103-022-03600-4","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]},"assertion":[{"value":"5 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"E.\u00a0Hildt gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}